Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9972730 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AALDH1A1GAACNR2 | |
| SCHEMBL3757791 | 0.80 | MET (0.41) | SMN1; SMN2KMT2ACNR2CNR1FFAR1 | |
| SCHEMBL3754114 | 0.79 | KCNA3 (0.41) | SMN1; SMN2GAAKCNA3 | |
| SCHEMBL1541608 | 0.74 | PDE4D (0.51) | SMN1; SMN2 | |
| SCHEMBL3761768 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2CNR2FFAR1FFAR4 | |
| SCHEMBL3392778 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL3767783 | 0.72 | KCNA2 (0.39) | GAACNR2CNR1KCNA3 | |
| SCHEMBL3386404 | 0.71 | SMN1; SMN2 (0.41) | SMN1; SMN2CNR2CNR1FFAR1FFAR4 | |
| SCHEMBL3752069 | 0.70 | KCNA3 (0.38) | CNR2CNR1KCNA3 | |
| SCHEMBL3751717 | 0.69 | KCNA3 (0.39) | SMN1; SMN2KMT2AALDH1A1GAAKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNH3 | SMN1; SMN2 3554/4885KMT2A 737/4885ALDH1A1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.